Every Form 4 that Biomarin Pharmaceutical Inc (BMRN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BMRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMRN filings page.
BIOMARIN PHARMACEUTICAL INC (BMRN) executive George Eric Davis, EVP and Chief Legal Officer, reported selling 17,557 shares of common stock on September 2, 2026 in an open market or private transaction at a weighted average price of $66.284 per share. After this sale, he directly holds 61,003 shares of BioMarin common stock. No Rule 10b5-1 trading plan is reported for this transaction. The footnote states the actual sale prices ranged from $66.271 to $66.39 per share.
BioMarin Pharmaceutical director Athena Countouriotis reported a routine equity compensation grant. On June 2, 2026, she acquired 7,490 shares of common stock in the form of restricted stock units, with no purchase price involved. Following this award, she directly holds 21,040 common shares.
BioMarin Pharmaceutical director Timothy P. Walbert reported an equity grant of 7,490 shares of common stock on June 2, 2026. The shares were received as restricted stock units granted on that date, with no purchase price involved, reflecting stock-based compensation rather than an open‑market trade.
Following the grant, Walbert directly holds 17,270 shares of BioMarin common stock. In addition, 416 shares are reported as indirectly held through Prairie Capital Ventures LLC. The filing does not show any sales or option exercises, only this award and an updated indirect holding line.
BioMarin Pharmaceutical director Maykin Ho reported an equity grant of company stock. On June 2, 2026, Ho acquired 7,490 shares of BioMarin common stock through a grant classified as restricted stock units, with no cash price per share.
Following this award, Ho directly holds 35,500 shares of BioMarin common stock. Because this was a compensation-related grant rather than an open-market trade, it mainly reflects ongoing equity-based director compensation rather than a change in personal investment stance.
HOMBACH ROBERT J. reported acquisition or exercise transactions in this Form 4 filing.
BIOMARIN PHARMACEUTICAL INC director Robert J. Hombach received a new equity award in the form of restricted stock units. On June 2, 2026, he was granted 7,490 shares of Common Stock as a compensation award, with no purchase price applicable to the grant.
Following this award, Hombach directly holds 49,360 shares of BioMarin common stock. This is a non-market transaction classified as a grant or award, rather than an open-market share purchase or sale.
BioMarin Pharmaceutical director Mark J. Enyedy received a stock-based compensation award. On June 2, 2026, he acquired 7,490 shares of common stock through a grant of restricted stock units, with no cash price per share. After this award, he directly holds 21,040 common shares.
Dere Willard H reported acquisition or exercise transactions in this Form 4 filing.
BIOMARIN PHARMACEUTICAL INC director Willard H. Dere received a grant of 7,490 shares of common stock in the form of restricted stock units on June 2, 2026. The grant is recorded at a price of $0.00 per share, reflecting that it is a compensation award rather than a market purchase.
Following this award, Dere directly holds 46,440 shares of BioMarin common stock as reported in this filing. The footnotes clarify that the transaction represents restricted stock units, with price not applicable.
CLARK IAN T reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical director Ian T. Clark received an equity grant. On June 2, 2026, he was awarded 7,490 restricted stock units tied to the company’s common stock, with no cash price per unit. Following this grant, he directly holds 14,490 common shares and units in total.
Bodem Barbara W. reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical Inc. director Barbara W. Bodem received a grant of 7,490 shares of common stock in the form of restricted stock units on June 2, 2026. The award had no purchase price, indicating it was compensation rather than an open-market buy. After this grant, she directly holds 21,045 common shares.
ANDERSON ELIZABETH M reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical director Elizabeth M. Anderson received a stock-based compensation grant. On June 2, 2026, she was awarded 7,490 shares of Common Stock in the form of restricted stock units at no cash cost, as the price is listed as not applicable.
After this grant, Anderson directly holds 41,940 shares of BioMarin Common Stock. This is a compensation-related award, not an open-market purchase or sale, and does not reflect a discretionary trading decision.
BioMarin Pharmaceutical executive Cristin Hubbard reported a routine tax-related share disposition. On this Form 4, 2,318 shares of Common Stock were withheld at $50.20 per share to cover tax obligations, described as a tax-withholding disposition. After this non-market transaction, Hubbard directly holds 42,472 shares.
BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg sold shares in an open-market transaction. On May 7, 2026, he sold 3,281 shares of common stock at $53.85 per share. After this sale, he directly owns 51,818 shares of BioMarin common stock.
BioMarin Pharmaceutical executive George Eric Davis, EVP and Chief Legal Officer, reported a routine share disposition related to taxes. On this date, 1,273 shares of common stock were withheld to cover tax obligations at $56.05 per share. After this tax-withholding transaction, he directly holds 78,560 shares of BioMarin common stock, indicating he retains a substantial equity position and that the filing reflects a compensation-related event rather than an open-market sale.
BioMarin Pharmaceutical EVP and Chief Technical Officer Charles Greg Guyer reported a tax-related share disposition. On the transaction date, 1,693 shares of common stock were withheld at a price of $56.05 per share to cover tax obligations, a non‑market transaction. After this event, he directly held 84,140 common shares.
BioMarin Pharmaceutical EVP and CFO Brian Mueller reported a tax-related share disposition. On March 17, 2026, 2,117 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly holds 123,314 common shares, indicating a routine, non–market sale event.
BioMarin Pharmaceutical Chief Executive Officer Alexander Hardy reported a routine share disposition related to taxes. On March 17, 2026, 4,252 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly held 214,635 shares.
BioMarin Pharmaceutical EVP and Chief Commercial Officer Cristin Hubbard reported compensation-related equity grants and a small tax withholding transaction. On March 16, 2026, she received 15,410 shares of Common Stock as restricted stock units and a stock option for 36,680 shares of Common Stock at an exercise price of $57.43 per share. The option grant vests 12/48ths on March 16, 2027, with the remaining 36/48ths vesting in equal monthly installments of 1/48th on the 16th day of each month thereafter.
On March 17, 2026, 1,245 shares of Common Stock were disposed of at $56.05 per share in a tax-withholding transaction to satisfy tax obligations, rather than an open-market sale. After these transactions, Hubbard directly held 44,790 shares of BioMarin Common Stock.
BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg reported routine equity compensation and related tax withholding. On March 16, 2026, he received 19,150 shares of common stock as a grant and a stock option for 45,600 shares at a $57.43 exercise price, both held directly.
The restricted stock units were granted on March 16, 2026, and the option grant vests 12/48ths on March 16, 2027 and 1/48th monthly thereafter. On March 17, 2026, 1,629 shares of common stock were disposed of at $56.05 per share to cover tax obligations, leaving him with 55,099 common shares directly owned.
BioMarin Pharmaceutical executive Charles Greg Guyer reported new equity awards and a tax-related share withholding. On March 16, 2026 he received stock options for 35,680 shares of common stock at an exercise price of $57.43 per share, vesting over four years starting March 16, 2027.
He also received a grant of 14,990 shares of common stock, described in a footnote as restricted stock units granted on March 16, 2026 with no purchase price. On March 13, 2026, 9,109 shares of common stock were withheld at $58.51 per share to cover tax obligations, which is not an open-market sale. Following these transactions and a one-share clerical correction, he directly holds 85,833 shares of common stock.
BioMarin Pharmaceutical executive George Eric Davis reported new equity awards and related tax withholding. He received a stock option for 34,690 shares of common stock at an exercise price of $57.43 per share, vesting in part on March 16, 2027 and monthly thereafter until 2036.
He also received 14,570 restricted stock units on March 16, 2026, while 7,177 shares of common stock were withheld to cover tax obligations at $58.51 per share. After these transactions, Davis directly holds 79,833 shares of common stock.
BioMarin Pharmaceutical EVP and CFO Brian Mueller reported routine equity compensation and related tax withholding. He received a stock option grant for 44,600 shares of common stock at an exercise price of $57.43 per share, vesting partly from March 16, 2027 through monthly installments until 2031. He was also granted 18,740 shares of common stock as restricted stock units with no purchase price.
To cover tax obligations on a prior vesting event, 9,945 shares of common stock were withheld at $58.51 per share, a non‑market disposition. Following these transactions, Mueller directly holds 125,431 common shares and the new option for 44,600 shares.
BioMarin Pharmaceutical CEO Alexander Hardy reported new equity awards and a routine tax withholding. On March 16, 2026, he received a grant of 89,200 stock options to buy common stock at an exercise price of $57.43 per share, expiring on March 15, 2036. The option grant vests 12/48 on March 16, 2027 and 1/48 on the 16th day of each month thereafter. He was also granted 62,440 restricted stock units on the same date, with price not applicable. On March 13, 2026, 2,941 shares of common stock were withheld at $58.51 per share to cover tax obligations. Following these transactions, Hardy directly owned 218,887 shares of BioMarin common stock.
BioMarin Pharmaceutical EVP and Chief Technical Officer Charles Greg Guyer sold common shares in an open-market transaction. On March 11, 2026, he sold 16,486 shares of BioMarin common stock at a weighted average price of $60.46 per share, with individual sale prices ranging from $60.39 to $60.62. After this sale, he directly held 79,953 shares of BioMarin common stock.
Guyer Charles Greg reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical executive Charles Greg Guyer, EVP and Chief Technical Officer, reported three equity awards credited on February 25, 2026. The awards represent performance-based restricted stock units earned for results over 2023–2025 tied to relative total shareholder return, development goals, and core operating margin, vesting on March 15, 2026 if he remains in service.
BIOMARIN PHARMACEUTICAL INC executive Gregory R. Friberg, EVP and Chief R&D Officer, reported an open-market sale of 6,326 shares of common stock on February 26, 2026. The shares were sold at a weighted average price of $60.3758 per share, with individual sale prices ranging from $60.36 to $60.51 according to the footnote. After this transaction, Friberg directly holds 37,578 shares of BioMarin common stock.
BioMarin Pharmaceutical EVP and Chief Legal Officer George Eric Davis reported both stock sales and equity awards. On February 26, 2026, he completed an open-market sale of 26,061 shares of common stock at $61.36 per share, leaving 72,453 shares held directly afterward.
On February 25, 2026, he acquired three blocks of common stock through grants or awards totaling 15,224 earned restricted stock units (RSUs), all at a stated price of $0.00 per share. These RSUs were earned under performance-based awards tied to relative total shareholder return, development goals, and core operating margin for 2023–2025, and will vest on March 15, 2026 subject to continued service and certain earlier-vesting events.
BioMarin Pharmaceutical executive Brian Mueller received multiple performance-based stock awards. On February 25, 2026, he acquired 6,683, 7,230, and 2,569 shares of common stock at $0 per share through grants classified as awards, not open-market purchases.
These shares come from Restricted Stock Units earned for performance over 2023–2025, based on relative total shareholder return, development goals, and core operating margin. The earned RSUs convert into common stock on a 1:1 basis and are scheduled to vest on March 15, 2026, subject to his continued service, with earlier vesting possible upon certain events. Following these awards, he directly owns 116,638 common shares.
BioMarin Pharmaceutical’s VP and Chief Accounting Officer, Rashmi Virendra Ramchandani, reported new equity awards. On January 20, 2026, she received 18,540 shares of common stock and a separate grant of 7,070 shares, both at a stated price of $0, which the footnotes describe as restricted stock units granted on that date. After these awards, she directly beneficially owned 25,610 common shares.
She was also granted a stock option covering 18,220 shares of common stock at an exercise price of $56.31 per share. The option becomes exercisable as to 12/48 of the grant on January 20, 2027, with the remaining 1/48 vesting on the 20th day of each month thereafter, and it expires on January 19, 2036. These transactions reflect equity compensation rather than open‑market buying or selling.
BioMarin Pharmaceutical insider Gregory R. Friberg, listed as Executive Vice President and Chief R&D Officer, reported a sale of 3,304 shares of BioMarin common stock on 09/30/2025 at a price of $54.16 per share. After the transaction, the reporting person beneficially owned 43,506 shares. The Form 4 was signed on 10/02/2025 by an attorney-in-fact.